Last reviewed · How we verify
Contrast
Contrast is a Small molecule drug developed by Cedars-Sinai Medical Center. It is currently in Phase 2 development. Also known as: contrast media, Gadavist, MultiHance, contrast agent.
Contrast is a treatment being studied in clinical trials for various conditions, including thyroid cancer, breast cancer, and colorectal cancer. It has been compared to other interventions such as surgery and laser ablation in clinical trials, specifically in the treatment of papillary thyroid microcarcinoma.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Contrast |
|---|---|
| Also known as | contrast media, Gadavist, MultiHance, contrast agent, low-osmolar, non-ionic contrast medium |
| Sponsor | Cedars-Sinai Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of New Magnetic Resonance Imaging Methods of the Brain
- Baylor Infant and Toddler Biomarker of Nutrition Study
- Conventional vs Pulsed RF in Coccydynia (NA)
- A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer (NA)
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- NHLBI-Emory Advanced Cardiac CT Reconstruction
- Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Contrast CI brief — competitive landscape report
- Contrast updates RSS · CI watch RSS
- Cedars-Sinai Medical Center portfolio CI
Frequently asked questions about Contrast
What is Contrast?
Who makes Contrast?
Is Contrast also known as anything else?
What development phase is Contrast in?
Related
- Manufacturer: Cedars-Sinai Medical Center — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: contrast media, Gadavist, MultiHance, contrast agent, low-osmolar, non-ionic contrast medium
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing